Substantial breakthrough discoveries, including the identification of lung cancer–specific oncogenic drivers (e.g., EGFR mutations, EML4-ALK fusion genes) and the development of molecular inhibitors of these pathogenic factors, have improved outcomes for patients with advanced-stage lung cancer. This evidence concerns the gene ALK and lung cancer.